Control BionicsASX:CBL -3.53% Market Cap is A$33.78 Mil as of Jun. 26, 2026. The stock has 7 warning signs investors should review. Among 866 Medical Devices & Instruments companies, Control Bionics ranks worse than 74.13% on this metric.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Control Bionics's share price for the quarter that ended in Dec. 2025 was A$0.061. Control Bionics's Shares Outstanding (EOP) for the quarter that ended in Dec. 2025 was 411.96 Mil. Therefore, Control Bionics's market cap for the quarter that ended in Dec. 2025 was A$25.13 Mil.
Control Bionics's quarterly market cap
declined
from Dec. 2024 (A$15.12 Mil) to Jun. 2025 (A$8.84 Mil) but then
increased
from Jun. 2025 (A$8.84 Mil) to Dec. 2025 (A$25.13 Mil).
Control Bionics's annual market cap
increased
from Jun. 2023 (A$7.87 Mil) to Jun. 2024 (A$10.36 Mil) but then
declined
from Jun. 2024 (A$10.36 Mil) to Jun. 2025 (A$8.84 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Control Bionics's Enterprise Value for Today is A$30.96 Mil.
Control Bionics (ASX:CBL) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Control Bionics Market Cap Related Terms
Control Bionics Market Cap Historical Data
* Premium members only.
The historical data trend for Control Bionics's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Control Bionics's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Control Bionics Market Cap vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Control Bionics's Market Cap distribution charts can be found below:
* The bar in red indicates where Control Bionics's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Control Bionics's Market Cap for the fiscal year that ended in Jun. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Control Bionics (ASX:CBL) has a Market Cap of A$33.78 Mil as of Jun. 26, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Control Bionics and its competitors. According to the industry distribution chart, Control Bionics ranks #642 out of 866 companies in the Medical Devices & Instruments industry, placing it in the top 74.1%.
Is Control Bionics' Market Cap too high?
Control Bionics' current Market Cap is A$33.78 Mil. Based on the distribution chart, Control Bionics ranks #642 out of 866 companies in the Medical Devices & Instruments industry, which is below the industry midpoint.
How does Control Bionics' Market Cap compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Control Bionics ranks #642 out of 866 companies for Market Cap. This places Control Bionics in the lower half of its industry. The industry median Market Cap is 121.29. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Medical Devices & Instruments company?
The median Market Cap among Medical Devices & Instruments companies is 121.29, based on 866 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Control Bionics and its competitors. For the Medical Devices & Instruments industry, the median Market Cap is 121.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Control Bionics's current Market Cap is A$33.78 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Control Bionics stock overvalued right now?
Based on GuruFocus' analysis, Control Bionics (ASX:CBL) is currently considered Significantly Overvalued. The stock's GF Value™ is A$0.03, compared to a current price of A$0.08 — trading 173.3% above its estimated fair value. The current Market Cap is A$33.78 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Control Bionics (ASX:CBL), the current Market Cap is A$33.78 Mil as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Control Bionics Ltd is engaged in the healthcare device business. It is involved in developing, commercializing, and selling assistive communications technology systems within the disability sector. Its core systems include NeuroNode Trilogy and NeuroNode3. These systems allow people with speech and movement difficulties to control a computer for speech generation, electronic communications, entertainment, and external control of other devices. Geographically, it derives a majority of revenue from North America and has its presence in Australia as well.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:CBL has been successfully added to your 